Shares in Nevro Corp. (NYSE:NVRO) are down over 10% in after-hours trading today after the medical device maker posted first quarter earnings that missed expectations on Wall Street. The Redwood City, Calif.-based company posted losses of $44.1 million, or $1.45 per share, on sales of $82.1 million for the three months ended March 31, seeing losses […]
Nevro Corp.
Nevro taps ex-Thoratec CEO Grossman | Personnel Moves, March 20, 2019
Nevro Corp. (NYSE:NVRO) said yesterday that it named former Thoratec CEO Keith Grossman to replace president & CEO Rami Elghandour after striking a deal with one of its investors, Broadfin Capital. Grossman re-joined Thoratec after taking over at Conceptus in December 2011 and leading it to a $1.1 billion sale to Bayer in June 2013 (he’d […]
Nevro shares down on Q4, 2018 miss
Shares in Nevro (NYSE:NVRO) fell today after the medical device maker released fourth quarter and full year 2018 earnings that missed loss-per-share expectations on Wall street. The Redwood City, Calif.-based company posted losses of $9.7 million, or 32¢ per share, on sales of $107.9 million for the three months ended December 31, seeing losses grow 97.1% […]
Stimwave calls Nevro patent suit ‘baseless, unfounded’
Stimwave today responded to a patent infringement suit filed by Nevro (NYSE:NVRO) stating that the claims made against the company are “completely baseless, unfounded and invalid.” In its suit, which was filed in the U.S. District Court for the District of Delaware last week, Nevro claims that Pompano Beach, Fla.-based StimWave infringed on patents related to […]
Nevro files patent infringement suit against Stimwave
Nevro (NYSE:NVRO) said today that it filed a patent infringement suit against Stimwave alleging that the company infringed on patents related to Nevro’s Senza system and HF10 therapy. The lawsuit, which was filed in the U.S. District Court for the District of Delaware yesterday, seeks preliminary and permanent injunctive relief against further infringement as well as […]
Si-Bone tops estimates with Q4 prelims | Wall Street Beat
Si-Bone (NSDQ:SIBN) said today that it expects to record fourth-quarter sales of $15.4 million to $15.6 million, up 12 – 13% from the same period last year. The company pegged its full-year sales for 2018 between $55.2 million and $55.4 million, up 15% from 2017. Analysts on Wall Street are expecting Si-Bone to post Q4 sales […]
Nevro fires back in spinal cord stim patent spat with Boston Scientific
Nevro (NYSE:NVRO) is seeking a reversal and remand for spinal cord stimulation patent infringement case against Boston Scientific (NYSE:BSX) that was ruled on this summer. A legal firm representing the company filed a brief this week seeking to overturn a decision from this summer which found a number of patent claims invalid as indefinite. In mid-July, a […]
Nevro posts Q3 earnings miss, sales beat
Nevro Corp. (NYSE:NVRO) yesterday posted third-quarter results that missed the consensus earnings forecast but beat on revenues. The Redwood City, Calif.-based neuromodulation firm reported losses of -$11.2 million, or -37¢ per share, on sales of $95.6 million for the three months ended Sept. 30, widening its losses by 84.3% on 16.3% sales growth compared with Q3 […]
Abbott alleges ex-marketing exec lifted its neuromod marketing playbook
Abbott (NYSE:ABT) this week accused a former marketing executive of purloining the marketing playbook for its neuromodulation business on his way out the door to a marketing job at competitor Nevro Corp. (NYSE:NVRO). In a lawsuit filed in the U.S. District Court for Northern Illinois, Abbott alleged that former neuromodulation global marketing product manager Blayne […]
BD promotes Polen to COO | Personnel Moves – October 3, 2018
Becton Dickinson (NYSE:BDX) said today it named current president Tom Polen as its new chief operating officer, filling a role that has been empty since 2016. Polen was appointed president in April 2017, and will continue to report to chairman and CEO Vincent Forlenza, the Franklin Lakes, N.J.-based company said. In his new position, Polen will […]
Nevro’s Q2 losses exceed expectations
Although it pared its second-quarter losses on strong revenue growth, Nevro Corp. (NYSE:NVRO) missed the consensus earnings forecast yesterday due to increased labor costs and a legal battle with spinal cord stimulation rival Boston Scientific (NYSE:BSX). Redwood City, Calif.-based Nevro posted losses of -$10.7 million, or -35¢ per share, on sales of $96.1 million for the three […]